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BACKGROUND: We compared the utility of a new response classification (MDA; based on computed tomography (CT), magnetic
resonance imaging (MRI), plain radiography (XR), and skeletal scintigraphy (SS)) and the World Health Organisation response
classification (WHO; based on XR and SS) in stratifying breast cancer patients with bone-only metastases with respect to
progression-free survival (PFS), overall survival (OS), and clinical response.
METHODS: We retrospectively reviewed 41 patients with bone-only metastatic breast cancer and assigned responses according to the
MDA and WHO criteria. We analysed whether the MDA or WHO response classifications correlated with PFS and OS.
RESULTS: With the MDA criteria, there were significant differences in PFS between patients classified as responders and those classified
as nonresponders (P¼0.025), but with the WHO criteria, there were not. Neither criteria distinguished responders from
nonresponders in terms of OS. MDA response criteria correlated better than WHO response criteria with clinical response
assessment.
CONCLUSIONS: The MDA classification is superior to the WHO classification in differentiating between responders and nonresponders
among breast cancer patients with bone-only metastases. Application of the MDA classification may allow bone lesions to be
considered measurable disease. Prospective study is needed to test the MDA classification among patients with bone metastasis.
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Bone is one of the most common sites to which breast cancer
metastasises (Coleman and Rubens, 1987; Hortobagyi, 1991). Up to
85% of patients with bone metastasis have other visceral
metastases during the course of the disease (Coleman and Rubens,
1987; Hortobagyi, 1991). Skeleton-related events such as bone pain
or pathologic fractures can substantially reduce the quality of life
for long-term survivors (Johnson et al, 2003). Standard treatments
for bone metastasis are anticancer agents, such as chemotherapy
and endocrine therapy. Bisphosphonates are also used to prevent
skeleton-related events. Response to treatment is typically
estimated by using a combination of methods, including dia-
gnostic imaging, measurement of biochemical markers, and
evaluation of patients’ symptoms.
Imaging modalities such as plain radiography (XR), skeletal
scintigraphy (SS), computed tomography (CT), magnetic
resonance imaging (MRI), and positron emission tomography (PET)
can be used to assess the response of bone lesions to treatment.
However, a comprehensive strategy for assessing bone tumour
response with these modalities is lacking, in part because of the
complex interactions between tumour cells and host cells during
bone turnover or remodeling. The presence of metastatic lesions
from breast cancer can influence bone homeostasis to favour bone
resorption or bone formation by affecting the activity of
osteoclasts or osteoblasts, thereby resulting in osteolytic, osteo-
blastic, or mixed lesions. Thus, accurate assessment of the
response of bone metastases to treatment requires visualising
not only the tumour burden but also structural changes in the
bone. Each of the aforementioned imaging techniques has
advantages and disadvantages in this regard. With XR, currently
the most convenient and inexpensive way of assessing treatment
response, 3–6 months and 430–50% mineral loss may be
required before changes become visible (Bellamy et al, 1987;
Howell et al, 1988). In addition, although XR can depict changes in
bone structure, it cannot depict the tumour itself. With SS, which
reflects bone blastic activity, it can also take 6 months or longer to
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sreliably detect a response because of the confounding effect of the
flare phenomenon, a spurious increase in radionuclide uptake
because of reparative mineralisation around healing metastases
(Coleman, 1991; Hortobagyi, 1991). Although CT is not com-
monly used to scan the whole body, CT can depict both structural
changes in the bone and anatomic changes associated with the
target tumour because of its multiple window settings. Magnetic
resonance imaging is optimally suited for showing spinal cord
status and changes in the bone marrow but not suited to showing
lytic or blastic change in bone structure. FDG PET, which reflects
high glucose metabolism, can be used to assess bone tumour
response in osteolytic metastatic lesions (Du et al, 2007), but it
lacks the detail necessary to detect anatomic changes in response
to treatment. Positron emission tomography–computed tomography
is a new method of combining metabolic and anatomic informa-
tion, but it is not yet commonly available for routine screening
(Even-Sapir, 2005). Thus, proper assessment of the response of
bone metastases to treatment requires consideration of different
aspects of the lesions, use of diagnostic imaging modalities in
appropriate combinations, and use of accurate, standardised
response criteria. Unfortunately, the complexities of this process
have led to the practise of considering bone lesions unmeasurable
disease.
Computed tomography and MRI are now commonly used in
clinical practise to assess bone tumour response, but the evidence
of an advantage of these imaging modalities over conventional XR
or SS is limited (Hamaoka et al, 2004). Until recently, no published
response criteria included findings from diagnostic CT or MRI.
The two established sets of criteria for assessing bone tumour
response, one from the International Union Against Cancer
(UICC) (Hayward et al, 1977) and the other from the World
Health Organisation (WHO, 1979), are 30 years old and based on
findings from XR or SS, which, as explained earlier, are limited in
that 6 months or more may be needed before responses become
visible. These criteria are not adequate as they do not incorporate
modern methods (e.g., CT and MRI) of assessing the response of
bone metastatic lesions to treatment. Another system in broad use,
the Response Evaluation Criteria in Solid Tumours classification
(Therasse et al, 2000), does not include bone lesions in response
assessments. Therefore, in the absence of established response
criteria, current response assessments for bone lesions using CT or
MRI are highly dependent on the physician’s judgment.
There is an urgent need to develop appropriate criteria for
assessing tumour response in the bone because patients with
bone-only metastatic disease have traditionally been excluded from
clinical trials owing to the lack of such criteria. Further, the
existence of an objective method with which community
physicians can evaluate their patients in a timely manner and
determine the effectiveness of treatment in eliciting a response in
bone metastases may affect the quality of the care provided to
these patients.
We hypothesised that CT or MRI is more accurate in assessing
the response of bone metastatic lesions to treatment than is XR or
SS because CT and MRI can visualise both bone and tumour and,
presumably, changes in both that are associated with treatment
(Hamaoka et al, 2004). To test this hypothesis, we compared the
ability of our ‘MDA classification’, which takes into account
findings from CT and/or MRI (Hamaoka et al, 2004) (Table 1), and
Table 1 The UICC, WHO, and MDA criteria for detection of bone response
Response type
Union International Against Cancer
(UICC)
a
World Health Organisation
(WHO)
b
Revised criteria for assessment of
bone response (MDA)
Target diagnostic imaging XR XR, SS XR, SS, CT, MRI
Complete response Disappearance of all known disease
Lytic lesions should have radiologic
evidence of calcification
Complete disappearance of all lesions on
X-ray or scan for at least 4 weeks
Complete fill-in or sclerosis of lytic lesion on
XR and CT
Disappearance of hot spots or tumour
signal on SS, CT, or MRI
Normalisation of osteoblastic lesion on XR
and CT
Partial response At least 50% decrease in size of measurable
lesions
Objective improvement in evaluable or
unmeasurable lesions
No new lesions or progressive lesions
Partial decrease in size of lytic lesions,
recalcification of lytic lesions, or decreased
density of blastic lesions for at least 4 weeks
Sclerotic rim about initially lytic lesion or
sclerosis of lesions previously undetected
on XR or CT
Partial fill-in or sclerosis of lytic lesion on XR
or CT
Regression of measurable lesion on XR, CT,
or MRI
Regression of lesion on SS (exclude rapid
regression
c)
Decrease in blastic lesion on XR or CT
No change or stable
disease
Unchanged, or between 25% increase and
50% decrease in size of measurable lesions
d
As a result of the slow response of bone
lesions, the classification of ‘no change’
should not be applied until at least 8 weeks
have passed from start of therapy
No change in measurable lesion on XR, CT,
or MRI
No change in blastic lesion on XR, CT,
or MRI
No new lesion on XR, SS, CT, or MRI
Progressive disease Mixed; some lesions persist while others
progress, or new lesions appear
Failure; some or all lesions progress and/or
new lesions appear. No lesions regress
Increase in size of existing lesions or
appearance of new lesions
Increase in size of any existing measurable
lesions on XR, CT, or MRI
New lesion on XR, SS (excluding flare
phenomena), CT, or MRI
Increase in activity on SS (excluding flare
phenomena) or blastic/lytic lesion on XR
or CT
Abbreviations: SS¼ skeletal scintigraphy; XR¼ plain radiography; CT¼ computed tomography; MRI¼ magnetic resonance imaging.
aCriteria are based on plain radiography;
the duration of response is to be measured from the start of therapy until either new lesions appear or any one existing lesion increases by 25% or more above its smallest
recorded size.
bOccurrence of bone compression or fracture and its healing should not be used as the sole indicator for evaluation of therapy.
cRapid osteolytic progression may
show decreased osteoblastic activity, resulting in regression of ‘hot spots’ on SS. XR or CT may be helpful in detecting progressive osteolysis and thus helping to identify
progressive disease in this situation.
dIf lesions that cannot be measured but are otherwise evaluable represent the bulk of disease and these lesions clearly do not respond even
though measurable lesions have improved, then the response is considered no change rather than an objective regression.
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sthe WHO classification, which does not, to stratify breast cancer
patients with bone-only metastases with respect to progression-
free survival (PFS), overall survival (OS), and clinical response.
MATERIALS AND METHODS
This study was approved by the institutional review board of The
University of Texas MD Anderson Cancer Center. We identified
46 patients with breast cancer and bone-only metastases who were
observed at MD Anderson Cancer Center and given systemic
treatment from October 1991 to September 2004 and who had CT,
XR, SS, and/or MRI examinations available for review (a total of
180 imaging examinations). We excluded the patients who were
given bisphosphonates because such treatment might affect the
appearance of bone on imaging studies. Five of the 46 patients
were not included in the statistical analysis because they under-
went additional treatment before the first response assessment 2–6
months after the initiation of systemic therapy. All patients
participated in clinical trials or standardised treatment protocols
and received systemic therapy (chemotherapy in 34 patients
and endocrine therapy in 7 patients). As this study focused on
comparing imaging response criteria and diagnostic imaging
before and after treatment, the results should not be affected by
the type of treatment or chemotherapy regimen. Images were
obtained at baseline (before the start of systemic therapy) and
at 2–6 months after the beginning of systemic therapy and/or at
11–13 months after the beginning of systemic therapy. The broad
time ranges for the two response assessment points were a result of
the retrospective nature of this study. The timing of follow-up
bone imaging commonly changed during the course of the study
according to the tumour and treatment status.
All images were reviewed and responses assigned independently
by two board-certified radiologists who specialise in musculo-
skeletal radiology (CMC, JEM) and who were blinded to patient
identities and outcomes. A response was assigned to each imaging
study (XR, SS, CT, or MRI). In addition, a response was assigned to
each patient on the basis of each of the three sets of imaging
response criteria (UICC, WHO, and MDA) (Table 1). The UICC
criteria are based only on findings from XR, the WHO criteria
include XR and SS, and the MDA criteria include findings from
XR, SS, CT, and MRI (Table 1). Therefore, XR images were read
three times – once in terms of the UICC criteria, again in terms of
the WHO criteria, and a third time in terms of the MDA criteria.
Skeletal scintigraphy images were read twice, in terms of the WHO
and MDA criteria. Computed tomography and MRI scans were
read only once, in terms of the MDA criteria. Responses were
categorised as complete response, partial response, stable disease,
or progressive disease. In total, 431 separate assessments (180
image sets) were made by each radiologist. Final responses were
confirmed by consensus, with discrepant diagnoses resolved
through discussion by the two readers in the presence of a third
investigator. Clinical evidence of response was obtained from
evaluation of (1) symptom changes, (2) trends in the levels of
tumour markers, and (3) all available radiographic images. If all
three criteria showed stable disease or if one or more criteria
showed disease progression, the findings were interpreted as
indicating no response. If one or more criteria showed response
and the others were stable, the findings were interpreted as
indicating a response.
To verify the advantage of the MDA criteria, we analysed
whether the use of a particular imaging modality or response
classification would distinguish responders from nonresponders in
terms of PFS or OS by using Kaplan–Meier analyses. To analyse
which particular imaging modality or response classification most
accurately reflected true bone tumour response, we analysed
agreement between the response assigned on the basis of imaging
results (response assigned on the basis of XR, SS, CT, or MRI alone
and response assigned according to the UICC, WHO, and MDA
criteria) and clinical response (complete or partial response vs
stable or progressive disease) using McNemar’s test and the kappa
coefficient test.
The retrospective nature of the data collection prevented our
obtaining enough XR and MRI scans for statistical analysis of XR
or MRI as single modalities. Less number of XR synchronised
images for each part by part, in turn precluded us from studying
the UICC criteria, which are based only on XR. Less number of
Table 2 Patients’ characteristics
Characteristic Number (%)
No. of patients 41
Age, median (range) 42 years (31–61 years)
Disease stage
I 7 (17)
II 21 (51)
III 4 (10)
IV 8 (20)
Unknown 1 (2)
T status
1 11 (27)
2 24 (59)
3 2 (5)
4 3 (7)
Unknown 1 (2)
N status
Positive 27 (66)
Negative 13 (32)
Unknown 1 (2)
Estrogen receptor status
Positive 27 (66)
Negative 13 (32)
Unknown 1 (2)
Progesterone receptor status
Positive 24 (59)
Negative 16 (39)
Unknown 1 (2)
Her2/neu status
Positive 5 (12)
Negative 13 (32)
Unknown 23 (56)
Bone metastatic site
Spine 36 (88)
Pelvis 18 (44)
Rib 14 (34)
Type of treatment
Chemotherapy 34
Endocrine therapy 7
Availability of images
At baseline and at 2–6 months after treatment
initiation
40
XR images 13
SS images 37
CT images 34
MRI images 13
At baseline and at 11–13 months after treatment
initiation
25
XR images 11
SS images 22
CT images 24
MRI images 12
Abbreviations: XR¼ plain radiography; SS¼ skeletal scintigraphy; CT¼ computed
tomography; MRI¼ magnetic resonance imaging.
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ssynchronised MRI is caused, which it is not standard to assess
bone tumour response. Therefore, the role of MRI was precluded
from the analysis. In addition, few image sets were available from
the later assessment time (at 11–13 months after treatment).
Therefore, we compared CT vs SS (to compare diagnostic imaging)
and the MDA classification, which includes CT, XR, and SS, vs the
WHO classification, which includes XR and SS, for the period
between baseline and 2–6 months after treatment had begun.
RESULTS
Patient characteristics
Patients’ characteristics are shown in Table 2. The median age at
diagnosis was 42 years (range, 31–61 years). We did not attempt to
separate patients into lytic and blastic subgroups because most
bone metastases had both lytic and blastic components. The
clinical response rates at 2–6 months after treatment initiation and
at 11–13 months after treatment initiation were 36.6 and 30.6%,
respectively. Only one patient died before 12 months after
treatment initiation. The median follow-up period was 37 months.
CT vs SS
Skeletal scintigraphy alone did not distinguish responders from
nonresponders in terms of either PFS (median time to progression,
10.3 months for responders vs 14.3 months for nonresponders,
P¼0.50; Figure 1B) or OS (median survival time, 61.9 months
for responders vs 59.9 months for nonresponders, P¼0.80).
Computed tomography alone also did not distinguish responders
from nonresponders in terms of either PFS (median time to prog-
ression, 19.1 months for responders vs 14.3 months for non-
responders, P¼0.18; Figure 1A) or OS (median survival time, 61.9
months for responders vs 34.4 months for nonresponders, P¼0.38).
However, CT alone tended to correlate better than SS alone with
true clinical response during the first 2–6 months after treatment
(kappa coefficients, 0.44 and 0.05, respectively; McNemar’s
P¼0.74 and 0.62, respectively; Table 3).
MDA classification vs WHO classification
The MDA classification, which includes SS and CT, distinguished
responders from nonresponders in terms of PFS (median time to
progression, 23.3 months for responders vs 5.5 months for
nonresponders; P¼0.025; Figure 2A). There was also a trend for
difference between responders and nonresponders in terms of OS,
but this difference was not significant (median survival time, 61.9
months for responders vs 34.4 months for nonresponders;
P¼0.13).
In contrast, the WHO classification did not distinguish
responders from nonresponders in terms of either PFS (median
time to progression, 12.4 months for responders vs 10.4 months for
nonresponders; P¼0.55; Figure 2B) or OS (median survival time,
61.9 months for responders vs 59.9 months for nonresponders;
P¼0.97). The MDA criteria tended to correlate better than the
WHO criteria with true clinical response during the first 2–6
months after treatment (kappa coefficients, 0.53 and 0.07;
McNemar’s P¼0.09 and 0.81, respectively; Table 3).
DISCUSSION
We previously reported a new set of response criteria, the MDA
criteria, that address the shortcomings of the UICC and WHO
criteria by taking into account CT and MRI findings (Hamaoka
et al, 2004) (Table 1). The MDA criteria also include detailed
descriptions of anatomic changes to be considered for each
diagnostic imaging modality. The MDA criteria take into account
the fact that the structure of bone rarely heals such that the bone
has the same appearance as the original even if treatment was
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Figure 1 Progression-free survival (PFS) curves for patients who
responded to treatment (complete or partial response) and those who
did not (stable or progressive disease) according to computed tomography
(CT) (A) or skeletal scintigraphy (SS) (B). CT seemed to distinguish
responders from nonresponders during the first 6 months after treatment
according to PFS, but SS did not.
Table 3 Agreement between imaging responses and clinical response
Clinical response
Imaging
response
Non-
responder
Res-
ponder
McNemar’s
test P-value
Kappa
coefficient
+95% Conf. Limit
MDA
Nonresponder 16 2 0.09 0.53 (0.27, 0.79)
Responder 7 13
WHO
Nonresponder 14 8 0.81 0.07 (–0.24, 0.39)
Responder 9 7
CT
Nonresponder 15 4 0.74 0.44 (0.13, 0.75)
Responder 5 9
SS
Nonresponder 16 9 0.62 0.05 (–0.27, 0.38)
Responder 7 5
Abbreviations: CT¼ computed tomography; SS¼ skeletal scintigraphy.
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ssignificantly effective (complete response). For example, according
to the MDA criteria, recalcification of the rim of an osteolytic
lesion on XR or CT (Figure 3A) is considered partial response, and
an increase in the area of lysis (Figure 3B) is considered
progressive disease.
The results of this retrospective image reading analysis indicate
that the MDA classification is superior to the WHO classification
in differentiating between responders and nonresponders among
breast cancer patients with bone-only metastases. With the MDA
classification, which takes into account CT findings, there were
significant differences in PFS between patients classified as
responders and those classified as nonresponders within 2–6
months after treatment. With the WHO classification, which does
not take into account CT findings, there were no such differences.
The MDA criteria tended to be more sensitive than the WHO
criteria for detecting response, although the number of cases
studied was too few to permit definitive conclusions on this point.
Computed tomography may be more sensitive than SS for
discerning responses.
Few reports are available documenting survival outcomes
according to response assessed using different response-assessment
schemes. One study showed that survival rates among patients
with ‘stable’ bone disease for more than 6 months according to the
UICC criteria were similar to those among patients with a ‘partial
response’ (Howell et al, 1988). In other words, in that study, the
UICC criteria did not distinguish between responders and
nonresponders in terms of survival rates.
Despite the widespread use of CT for assessing tumour response
of solid non-bone tumours, the use of CT for assessing bone
tumour response has yet to be established. We did find one
published prospective study in which CT was used to assess the
response of lytic metastatic bone lesions in 20 patients and CT
response was compared with change in patients’ symptoms
(Bellamy et al, 1987). In this study, improvement observed on
CT was associated with improvement in symptoms in two-thirds of
the patients. This study has shown that patients with a response
on CT may have had longer PFS and OS than those who did not
show a response.
The lower correlation between the primarily SS-based WHO
criteria and response than between the MDA criteria and response
could have resulted from several factors, including high false-
positive rates caused by conditions other than tumour (e.g.,
fracture, arthritis, infection) (Galasko and Doyle, 1972; Citrin et al,
1977; Coleman et al, 1988b; Tubiana-Hulin, 1991; Rybak and
Rosenthal, 2001) or ‘flare’ phenomena (Coleman, 1991; Hortobagyi,
1991). In one prospective report, in 75% of patients with breast
cancer whose bone metastases showed a partial response (healing
of lytic metastases on XR), there was increased tracer uptake on SS
during the first 3 months after treatment because of new bone that
had formed during the repair process. Such a situation could
well be interpreted as progressive disease; however, after 6 months,
the accumulation gradually decreased (Coleman et al, 1988a).
Another possible explanation for the poor correlation between
WHO response and clinical response is that rapid progression of
disease, when overwhelming destruction allows little chance for
new bone to form, is sometimes depicted by SS as a reduction in
isotope uptake (‘cold spots’) (Galasko and Doyle, 1972; Condon
et al, 1981; Cook and Fogelman, 2000). In our opinion, deter-
mining the final response of bone metastases solely on the basis of
changes in radionuclide uptake over time is not appropriate
(Libshitz and Hortobagyi, 1981).
Our findings suggest that the MDA criteria, which incorporate
findings from CT scans, are superior to the WHO criteria, which
are based primarily on SS, for predicting PFS in patients who
respond to treatment. This confirms the importance of using
multiple imaging modalities to accurately determine response. We
found a statistically significant difference only for the MDA-to-
WHO comparison for PFS. However, we speculate that the lack of
significant differences in other comparisons may have been
because of the limited number of patients who had multiple image
sets available for retrospective image reviews. To increase the
likelihood of identifying patients who had had imaging performed
at regular intervals after treatment, we selected patients who had
been treated according to the structured, well-organised treatment
plans required of investigative research protocols; this necessarily
limited the number of patients and images available for review.
In summary, the results of this image reading study suggest that
the MDA classification is superior to the WHO classification for
assessing the response of bone metastases to treatment. However,
these findings need to be confirmed prospectively. In addition, in
future prospective studies, the effect of bisphosphonates should be
studied because bisphosphonates are now commonly used in
patients with bone metastasis. Further, PET–CT, which fuses
images from PET and CT, may yield better detection of bone
tumour response because of the addition of information on
glucose metabolism to the anatomic details provided by CT. One
study showed 80.5% agreement between CT osteoblastic response
and PET positivity change (positive to negative) in osteolytic
metastases (Du et al, 2007). Positron emission tomography also
has the advantage of permitting quantification of response – bone
tumour response might be quantified using the maximum
standard uptake value (Stafford et al, 2002). That indicates that
PET can be a sensitive modality for monitoring osteolytic bone
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Figure 2 Progression-free survival (PFS) curves for patients who
responded to treatment (complete or partial response) and those who
did not (stable or progressive disease) according to the MDA criteria (A)
and the World Health Organisation (WHO) criteria (B). The MDA criteria
(which incorporate findings from CT scans) distinguished responders from
nonresponders during the first 6 months after treatment according to PFS;
in other words, patients classified as responders according to the MDA
criteria (which included CT findings) had a better prognosis than did those
classified as nonresponders. In contrast, the WHO classification (based on
SS findings) did not differentiate between responders and nonresponders
in terms of PFS.
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stumour response. Although PET scanning has the potential to yield
false-positive results with the use of granulocyte colony-stimulating
factors in patients receiving myelosuppressive chemotherapy, the
CT aspect of PET–CT may compensate for that potential problem
with its anatomic information (Even-Sapir, 2005; Israel et al, 2006).
As the cost of PET–CT gradually becomes more reasonable, there
is a great possibility that PET–CT may become the standard for
assessing the response of bone metastasis.
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